Cargando…
依布替尼通过新型途径克服弥漫大B细胞淋巴瘤细胞耐药机制的研究
OBJECTIVE: To explore the mechanism of ibrutinib on drug resistance diffuse large B-cell lymphoma (DLBCL) cells. METHODS: DLBCL cell line was cultured with mesenchymal stem cells (MSC), and DLBCL cells which migrated and adhered to MSC under microscope was counted. The secretion of CXCL12 by MSC wer...
Autor principal: | Sotomayor, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342183/ https://www.ncbi.nlm.nih.gov/pubmed/29365396 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.006 |
Ejemplares similares
-
伊布替尼联合替莫唑胺治疗老年初治原发中枢神经系统弥漫大B细胞淋巴瘤一例
Publicado: (2020) -
下调HOTAIR通过提高PTEN表达逆转HCC827细胞吉非替尼耐药
Publicado: (2020) -
烟草烟雾通过ROS/Sirt3/SOD2通路诱导NSCLC细胞吉非替尼耐药
por: Yawan, ZI, et al.
Publicado: (2023) -
伊布替尼治疗过程中华氏巨球蛋白血症向弥漫大B细胞淋巴瘤克隆同源性转化一例报告并文献复习
Publicado: (2020) -
TRIM24介导肺癌细胞吉非替尼耐药机制探讨
Publicado: (2016)